

FASN Conjugated Antibody

Catalog No: #C38133



Package Size: #C38133-AF350 100ul #C38133-AF405 100ul #C38133-AF488 100ul
 #C38133-AF555 100ul #C38133-AF594 100ul #C38133-AF647 100ul
 #C38133-AF680 100ul #C38133-AF750 100ul #C38133-Biotin 100ul

Orders: order@signalwayantibody.com
 Support: tech@signalwayantibody.com

Description

Product Name	FASN Conjugated Antibody
Host Species	Rabbit
Clonality	Polyclonal
Species Reactivity	Hu Ms Rt
Specificity	The antibody detects endogenous level of total FASN antibody.
Immunogen Description	Recombinant protein of human FASN.
Conjugates	Biotin AF350 AF405 AF488 AF555 AF594 AF647 AF680 AF750
Other Names	FASN;FAS;MGC14367;MGC15706;OA-519;SDR27X1 ;
Accession No.	Swiss-Prot#:P49327NCBI Gene ID:2194
Uniprot	P49327
GeneID	2194;
Excitation Emission	AF350: 346nm/442nm AF405: 401nm/421nm AF488: 493nm/519nm AF555: 555nm/565nm AF594: 591nm/614nm AF647: 651nm/667nm AF680: 679nm/702nm AF750: 749nm/775nm
Calculated MW	272
Formulation	0.01M Sodium Phosphate, 0.25M NaCl, pH 7.6, 5mg/ml Bovine Serum Albumin, 0.02% Sodium Azide
Storage	Store at 4°C in dark for 6 months

Application Details

Suggested Dilution:

AF350 conjugated: most applications: 1: 50 - 1: 250

AF405 conjugated: most applications: 1: 50 - 1: 250

AF488 conjugated: most applications: 1: 50 - 1: 250

AF555 conjugated: most applications: 1: 50 - 1: 250

AF594 conjugated: most applications: 1: 50 - 1: 250

AF647 conjugated: most applications: 1: 50 - 1: 250

AF680 conjugated: most applications: 1: 50 - 1: 250

AF750 conjugated: most applications: 1: 50 - 1: 250

Biotin conjugated: working with enzyme-conjugated streptavidin, most applications: 1: 50 - 1: 1,000

Background

Fatty acid synthase (FASN) catalyzes the synthesis of long-chain fatty acids from acetyl-CoA and malonyl-CoA. FASN is active as a homodimer with seven different catalytic activities and produces lipids in the liver for export to metabolically active tissues or storage in adipose tissue. In most other human tissues, FASN is minimally expressed since they rely on circulating fatty acids for new structural lipid synthesis (1). Recently, increased expression of FASN has emerged as a phenotype common to most human carcinomas. In breast cancer, immunohistochemical staining showed that the levels of FASN are directly related to the size of breast tumors (2). Studies also showed that FASN is highly expressed in lung and prostate cancers and that FASN expression is an indicator of poor prognosis in breast and prostate cancer (3-5). Furthermore, inhibition of FASN is selectively cytotoxic to human cancer cells (5). Thus, increased interest has focused on FASN as a potential target for the diagnosis and treatment of cancer as well as metabolic syndrome (6,7).

Note: This product is for in vitro research use only